We are live on ! Find out more
NSRX icon

Nasus Pharma

9 hedge funds and large institutions have $7.84M invested in Nasus Pharma in 2026 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.23% less ownership

Funds ownership: 18.36% → 18.13% (-0.23%)

10% less funds holding

Funds holding: 10 → 9 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

69% less capital inflows, than outflows

Capital inflows: $41.9K | Capital outflows: $135K

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$8.3K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$77K
2
XTX Topco
XTX Topco
Cayman Islands
-$58.2K

NSRX Hedge Fund Activity: Q3 2026 in Review

9 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q3 2026, worth a combined $7.84M — up 4.1% from $7.53M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NSRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, adding an estimated $8.3K. The largest seller was Citadel Advisors, exiting entirely with an estimated $77K sold.

  • 9 institutional investors held Nasus Pharma (NSRX) as of Q3 2026, down from 10 in Q2 2026.
  • Funds reported $7.84M of Nasus Pharma stock for Q3 2026, up 4.1% quarter-over-quarter.
  • 1 fund opened new Nasus Pharma positions in Q3 2026 and 2 closed out, a net change of -1 holder.
  • The largest Nasus Pharma buyer in Q3 2026 was Renaissance Technologies, an estimated $8.3K added.
  • The largest Nasus Pharma seller in Q3 2026 was Citadel Advisors, an estimated $77K sold.

Based on aggregated 13F filings for Q3 2026.